Edgewise Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference on May 20, 2026
Edgewise Therapeutics (Nasdaq:EWTX) announced that company leadership will present at the RBC Capital Markets Global Healthcare Conference on May 20, 2026, at 10:00 am ET.
Rhea-AI Summary
Edgewise Therapeutics (Nasdaq:EWTX) announced that company leadership will present at the RBC Capital Markets Global Healthcare Conference on May 20, 2026, at 10:00 am ET.
The presentation will be available via live webcast through the Edgewise Events & Presentations page and will remain accessible for replay for a limited time.
Positive
- None.
Negative
- None.
Details
News Market Reaction – EWTX
On May 12, the day this news came out, EWTX closed 1.59% below the previous close.
Data tracked by StockTitan Argus for the May 12 session.
Key Figures
- Conference presentation time
- 10:00 am ET
- RBC Capital Markets Global Healthcare Conference on May 20, 2026
Historical Context
-
Quarterly results and pipeline updates in muscular dystrophy and cardiovascular programs.
-
Stock option inducement grants to new non-executive employees under 2024 plan.
-
Additional inducement stock options granted to new non-executive employees.
-
Positive long-term sevasemten data in Becker muscular dystrophy with sustained stabilization.
-
Announcement of Leerink Global Healthcare Conference presentation and webcast access details.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
The presentation will be webcast live; a link for the webcast can be found on the Edgewise Events & Presentations page and will be accessible for replay for a limited time following the conference. It is recommended that users connect to the live webcast several minutes prior to the start to ensure a timely connection.
About Edgewise Therapeutics
Edgewise Therapeutics is a leading muscle disease biopharmaceutical company developing novel therapeutics for muscular dystrophies and serious cardiac conditions. The Company's deep expertise in muscle physiology is driving a new generation of novel therapeutics. Sevasemten is an orally administered first-in-class fast skeletal myosin inhibitor in late-stage clinical trials in Becker and Duchenne muscular dystrophies. EDG-7500 is a novel cardiac sarcomere modulator for the treatment of symptomatic hypertrophic cardiomyopathy, currently in Phase 2 clinical development. EDG-15400 is a novel cardiac sarcomere modulator for the treatment of heart failure, currently in Phase 1 clinical development. The entire team at Edgewise is dedicated to our mission: changing the lives of patients and families affected by serious muscle diseases. To learn more, go to edgewisetx.com or follow us on LinkedIn and X.
View original content to download multimedia:https://www.prnewswire.com/news-releases/edgewise-therapeutics-to-present-at-the-rbc-capital-markets-global-healthcare-conference-on-may-20-2026-302768502.html
SOURCE Edgewise Therapeutics
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.